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Cell Injury, Repair, Aging and Apoptosis
Neuroprotective Effect of Oligodendrocyte Precursor
Cell Transplantation in a Long-Term Model of
Periventricular Leukomalacia
Daniel J. Webber,*†‡ Marka van Blitterswijk,*†
and Siddharthan Chandran*†‡
From the Anne McLaren Laboratory for Regenerative Medicine,*
and the Cambridge Centre for Brain Repair,† University of
Cambridge, Cambridge; and the Euan MacDonald Centre,‡
University of Edinburgh, Chancellors Building, Little France
Crescent, Edinburgh, United Kingdom
Perinatal white matter injury, or periventricular leu-
komalacia (PVL), is the most common cause of brain
injury in premature infants and is the leading cause of
cerebral palsy. Despite increasing numbers of surviv-
ing extreme premature infants and associated long-
term neurological morbidity, our understanding and
treatment of PVL remains incomplete. Inflammation-
or ischemia/hypoxia-based rodent models, although
immensely valuable, are largely restricted to repro-
ducing short-term features of up to 3 weeks after
injury. Given the long-term sequelae of PVL, there is a
need for subchronic models that will enable testing of
putative neuroprotective therapies. Here, we report
long term characterization of a neonatal inflamma-
tion-induced rat model of PVL. We show bilateral ven-
triculomegaly, inflammation, reactive astrogliosis,
injury to pre-oligodendrocytes, and neuronal loss 8
weeks after injury. We demonstrate neuroprotective
effects of oligodendrocyte precursor cell transplanta-
tion. Our findings present a subchronic model of PVL
and highlight the tissue protective effects of oligoden-
drocyte precursor cell transplants that demonstrate
the potential of cell-based therapy for PVL. (Am J
Pathol 2009, 175:2332–2342; DOI: 10.2353/ajpath.2009.090051)
Premature, low-birth weight infants are commonly diag-
nosed with perinatal white matter damage, which leads
to long-term neurological deficits including cerebral
palsy.1–4 Congenital encephalomyelitis was described
almost 150 years ago, a disease in newborn children
characterized by pale softened zones of degeneration
within the deep white matter surrounding lateral ventri-
cles and is now often referred to as periventricular leu-
komalacia (PVL).5 The white matter damage that occurs
in preterm infants has more recently been shown to be
also accompanied by significant cerebral-cortex and
deep-gray matter abnormalities leading to neurodegen-
eration and altered neurobehavioral performance.6
PVL is characterized by selective oligodendrocyte pre-
cursor cell (OPC) loss resulting in delayed or disrupted
myelination, white matter atrophy and ventriculomegaly,
neuronal loss, and cyst and scar formation. Extreme pre-
mature birth (approximately 23 to 32 weeks) accompa-
nied by inflammation or infection corresponds to the
period when immature dividing and differentiating oligo-
dendrocytes predominate in the cerebral white mat-
ter.7–10 PVL has a complex etiology. The two most impor-
tant determinants are cerebral hypoperfusion and
maternal intrauterine infection. Periventricular white mat-
ter is susceptible to hypoperfusion due to the compara-
tive immaturity of the periventricular vasculature of the
preterm infant.11,12 Early oligodendrocyte lineage cells
are vulnerable to the consequences of hypoperfusion
and subsequent microglial and astrocytic activation on
account of amplified glutamate receptor-mediated re-
sponses and lack of efficient antioxidant protection.13–18
Maternal infection, recently implicated as a causative
factor in the pathogenesis of PVL,19–23 is believed to
initiate an inflammatory/cytokine cascade that results in
the release of early-response pro-inflammatory cytokines
such as tumor necrosis factor– (TNF-), interleukin1 
(IL-1) and interleukin6 (IL-6), and causes damage to
immature oligodendrocytes.24 TNF- appears to have a
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particularly important role in PVL pathogenesis with in
vitro evidence suggesting direct damage to OPCs,25,26
while IL-1 and IL-6 modulate injury indirectly.27,28
Although cells of the oligodendrocyte lineage are re-
garded as the primary target in the pathogenesis of PVL,
there is increasing evidence that neonatal white matter
damage is accompanied by gray matter abnormalities,
including neuronal loss, impaired axonal guidance, and
altered synaptogenesis.6,29 Premature newborns af-
fected by PVL often have smaller cerebral cortex and
deep gray matter volumes, reduced cortical neurons,
and alterations in the orientation of central white matter
fiber tracts.6,30–32 Together, these data suggest that de-
veloping neurons, like immature oligodendrocyte lineage
cells, are also vulnerable to injury caused by inflamma-
tory response or hypoxia.
Aspects of PVL have been modeled by ischemia/hyp-
oxia and inflammation-mediated rodent models. Animal
models of hypoxia-ischemia have clearly shown that
following brain injury there is reduced myelination, en-
larged ventricles, loss of neurons and damage to ax-
ons and dendrites and altered neurobehavioral perfor-
mances.33–39 Experimentally induced inflammation has
been used in a number of studies to model PVL pathol-
ogy and test potential treatments.23,40–42 Administration
of the endotoxin lipopolysaccharide (LPS), a potent in-
ducer of innate immune response and inflammation,43,44
either intracerebrally during early neonatal period, intra-
uterine or peritoneally to a pregnant mother results in
inflammation and hypomyelination.20,22,23,38 Moreover, in
animal models of LPS-induced PVL neuronal loss and a
reduction in neurite length in the parietal cortex has been
observed.42,45 In vitro evidence suggests LPS is not di-
rectly toxic to OPCs, but causes injury through the acti-
vation of Toll-like receptor 4-positive microglia, which is a
source of pro-inflammatory cytokines, nitric oxide, and
free radicals.44–46 Furthermore, it has been shown that
LPS-induced inflammation increases the susceptibility of
white matter to injury in response to otherwise “harmless”
subthreshold hypoxic-ischemic insult.47 Current models
of PVL are typically short term, with studies using either
hypoxia-ischemia or inflammation rarely extending anal-
ysis beyond 14 days. There is therefore a need to eval-
uate the longer-term, subchronic consequences of LPS
injury and specifically address whether hypomyelination
and neuronal injury are self-limiting or indeed spontane-
ously repair.
Cellular therapeutic strategies are predicated on cell
replacement and/or tissue protection independent of
specific cellular differentiation. Progenitor cells including
OPCs have previously been used for cellular replace-
ment of damaged or lost cells in a variety of CNS injury
models where damage to myelin and neuronal loss
occur.48,49–53 Furthermore, there is accumulating evi-
dence that implicates progenitor cell mediated neuropro-
tection through a variety of mechanisms including graft
derived neurotrophic support independent of directed
differentiation.54,55 Moreover, there is evidence to sug-
gest that OPCs secrete factors that are capable of sup-
porting neuronal survival,56–61 thus suggesting they may
be a potential therapeutic source for replacing lost or
damaged cells and protecting healthy tissue following
neonatal brain injury. In this study we have examined the
subchronic effects of LPS induced injury and then




Intracerebral injections of LPS (1 mg/kg, n 25) or saline
(n  14) to 5-day-old (P5) rats were performed as previ-
ously described.23 Briefly, postnatal day 5 (P5) Sprague
Dawley rats (Harlan, UK) were anesthetized by placing
them on ice, before being placed in full body mold to
prevent movement during the injection. Bregma was
identified using white light lamp. A needle was then used
to puncture the skin and skull at the following coordinates
from bregma: anteroposterior (AP)1 mm, medial-lateral
(ML) 1 mm, dorsal-ventral (DV) 2 mm.22 The dose of
LPS was chosen based on the results of previous studies
demonstrating white and gray matter injury.22,23 Using a
10-l precise Hamilton micropipette, a 1-l solution of
LPS (10 mg/kg) was infused over 3 minutes into the
periventricular area of the neonatal rat brain (see Supple-
mental Figure 1 at http://ajp.amjpathol.org). The needle
was left in situ for a further 3 minutes before slowly being
withdrawn. The P5 rats were then placed on a heated
blanket before being return to the mother. On weaning
the rats were given food and water ad libitum.
Tissue Dissection
All cell culture reagents were obtained from Invitrogen/
Gibco (UK) unless otherwise specified. Experimental an-
imals in this study were used under the United Kingdom
Animals (Scientific Procedures) Act 1986. Green fluores-
cent protein (GFP) neonatal rats [gift from Dr. Okabe,
postnatal day (P)0-2] were terminated by lethal injection
of Euthatal (sodium pentobarbital, 0.05 ml). Following
removal of meninges, cortex was isolated and manually
minced before enzymatic digestion with 0.1% trypsin/
EDTA, followed by 0.001% DNase (Sigma, UK) and cen-
trifugation at 1500 rpm for 5 minutes. The resulting cell
pellet was resuspended in triturating solution (containing
0.05% w/v trypsin inhibitor, 1% w/v bovine serum albu-
min, and 0.002% w/v DNase in Hanks balanced salt
solution) and triturated using a flamed glass pipette to
obtain a single cell suspension.
Mixed Glial Preparation
To obtain OPC populations for transplantation neonatal
cerebral cortex suspensions were seeded onto flasks
(Poly-D-Lysine-coated, approximately 1.5  106 cells
seeded/T75 flasks) and maintained in serum buffer [Dul-
becco’s modified Eagle’s medium (4.5 g/L glucose) sup-
plemented with 1% penicillin-streptomycin-fungizone,
and 10% fetal calf serum, v/v] for 7 days with complete
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media changes 24 hours, 3 days, and 6 days, as previ-
ously described.62
Transplantation of OPCs into Rat Cortex
One day before transplantation experiments, GFP-mixed
glial preparations (7 days) were shaken in an incubated
chamber for 1 hour to remove top dwelling microglia.
Media was removed and fresh Dulbecco’s modified Ea-
gle’s medium (with 1% penicillin-streptomycin-fungizone,
10% fetal calf serum) was then added and the mixed glial
preparations returned to incubator for at least 1 hour.
Flasks were then shaken overnight (16 to 18 hours) to
remove the OPCs ready for transplantation. OPCs were
maintained as a single cell suspension at 8.0  104
cells/l in Hanks balanced salt solution on ice.
The care and treatment of the animals was in accor-
dance with United Kingdom Animals (Scientific Proce-
dures) Act 1986. For the transplantation experiments,
Sprague-Dawley postnatal day 11 (P11) neonatal animals
previously lesioned at P5 were anesthetized using isoflu-
rane (see Supplemental Figure 1 at http://ajp.amjpathol.
org). GFP-OPCs were implanted 1 week after injury. Ani-
mals were divided into three groups: LPS-lesioned followed
by GFP-OPC transplant (n  8); LPS-lesioned, followed by
vehicle control transplant (n  8); and control-lesioned, no
transplant (saline, n  6). Animals were placed into a neo-
natal adaptor to prevent movement during the injection.
Coordinates were taken from bregma: AP 1 mm and ML
1 mm. GFP-OPCs (8.0  104 cells/l) or saline control
was then drawn into a Hamilton syringe and 1 l injected
unilaterally above the ventricle at a depth of DV2mmover
3 minutes. The syringe was left in situ for a further 3 minutes
before withdrawing slowly. The pup was then placed on a
heated blanket before being returned to the mother.
Immunohistochemistry
Animal groups (n  6) were terminated at 8 weeks (when
the rats reached young adulthood, see Supplemental
Figure 1 at http://ajp.amjpathol.org) following LPS lesion-
ing at P5, using an overdose of sodium pentobarbital (80
mg/kg i.p.), and perfused transcardially with 0.1 M/L PBS
followed by 4% paraformaldehyde in 0.1 M/L PBS (pH
7.4). The brains were then removed and post-fixed for 4
hours before being immersed in 30% sucrose solution.
Immunohistochemistry was performed using standard
procedures as previously described.62 Fixed brains were
sectioned coronally at 40 m using a freezing microtome
(Leica, UK). A one-in-twelve series of sections was pro-
cessed for each stain unless otherwise stated. Tissue
was washed in Tris-buffered saline (TBS) and subse-
quently blocked in TBS/0.2% Triton X-100/5% normal
donkey serum for 2 hours before overnight incubation at
4°C with primary antibody. Tissue sections were subse-
quently washed and appropriate secondary antibodies
(1:500; Molecular Probes, Paisley, UK) were applied.
Finally, the sections were washed three times for 5 min-
utes each in Tris-buffered non-saline before being
mounted on gelatinized slides and coverslipped using
Flurosave (Calbiochem, Nottingham, UK). The following
antibodies were used: anti-GFP (1:500, rabbit & goat,
Molecular Probes); neuronal and neurofilament markers;
neuronal nuclei (NeuN) (1:400, mouse, Chemicon); dou-
blecortin (1:500, goat, Santa Cruz Biotechnology, Heidel-
berg, Germany); neurofilament nonphosphorylated anti-
body SMI 32 (1:500, Abcam, Cambridge, UK); astrocyte
markers; glial fibrillary acidic protein (GFAP, 1:500,
mouse CY3 conjugated, Sigma, Dorset, UK); glial cell
marker S100 (1:400, rabbit, DAKO, Ely, UK); oligoden-
drocyte markers; chondroitin sulfate proteoglycan, NG2
(1:200, kind gift of W. Stallcup); oligodendrocyte lineage
transcription factor 2 (Olig2, 1:500, rabbit, Millipore,
Watford, UK); oligodendrocyte marker RIP recognizing
2,3-cyclic nucleotide 3-phosphodiesterase (CNPase) (1:
1000, Millipore, Watford, UK); oligodendrocyte marker O4
(1:1000, Chemicon); and inflammatory marker microglial
cell marker OX-42 (1:400, cd11b, mouse, Chemicon). For
confocal analysis, stacks of images were captured on a
Leica TCS-NT-UV confocal laser scanning microscope us-
ing a 63  1.25 N.A. Leica lens. Typical stacks were com-
posed of 10 to 20 optical sections of 1 m thickness taken
at 0.8 m intervals. Sequential acquisitions were performed
in the different channels to avoid anymisinterpretation of the
results due to signal cross talk.
Real-Time PCR
Total cellular RNA was extracted from snap frozen LPS-
lesioned (n  4) and saline control-lesioned (n  4)
animals using the RNeasy Mini isolation kit (Qiagen).
RNase-free-DNase (New England Biolabs)-treated RNA
samples (2 g) were reverse transcribed in 100 l with
random hexamers using MMLV RT (Invitrogen Ltd, UK)
according to the manufacturer’s protocol. PCR was con-
ducted in 25 l reaction volume using 2 l cDNA synthe-
sized as described above and forward and reverse prim-
ers IL-1  forward: 5-GCTTCCTTGTGCAAGTGTCTG-3,
reverse: 5-CTGTCCATTGAGGTGGAGAGC-3; TNF-
forward: 5-CCACGTCGTAGCAAACCACCAAGTG-3,
reverse: 5-CACAGAGCAATGACTCCAAAG-3; and hy-
poxanthine phosphoribosyl-transferase (HPRT) forward:
5-AGCTACTGTAATGATCAGTCAACG-3, HPRT re-
verse: 5-GAGGTCCTTTTCACCAGCA-3), with BioTaq
polymerase (BioLine Ltd, UK). To compensate for vari-
able RNA and cDNA yields, the expression of HPRT was
used as a control for which the optimal number of PCR
cycles for linear amplification was determined. The am-
plification products were analyzed by agarose gel
electrophoresis.
Preparation of Semithin Resin Sections
Animals for resin embedding (n  5 per group) were
fixed using 4% glutaraldehyde in PBS. The brain was
dissected out as previously described and sections post-
fixed overnight in 4% paraformaldehyde. The brain was
then sectioned so that a piece of tissue including the
cortex, corpus callosum, and periventricular region was
transferred to 4% glutaraldehyde for 48 hours before
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embedding. Sections were washed in PBS, before being
placed in a 2% osmium tetraoxide solution (Oxkem Lim-
ited, Reading, UK) overnight at 4°C. The next day the
tissue was dehydrated in a graded series of ethanol
washes (70% ethanol for 15 minutes; 95% ethanol for 15
minutes; 100% ethanol for 10 minutes, repeated twice).
Resin (TAAB Labs, Aldermaston, UK) impregnation was
performed by washing with propylene oxide (twice for 15
minutes) and then with propylene oxide/resin (50:50, for 3
hours). Following two immersions in 100% resin (mini-
mum of 6 hours each), sections were embedded individ-
ually in beam capsules and hardened at 60°C over 24
hours. Semithin sections were cut using 6-mm glass
knives on a Leica RM2065 microtome. These were
placed on Polysine slides (VWR international, Lutter-
worth, UK) in a droplet of distilled water and flattened by
placing and manually rotating the slide on a heat plate.
Once sections were dry, the slide was flooded with tolu-
idine blue (5% in a Borax solution) and heated again until
vapors evolved. The stain was removed in a stream of hot
water and sections dried on a hot plate. Finally slides
were cleared in xylene, before being mounted using
distyrene, platicizer, xylene (D.P.X.) mountant solution.
Semithin sections (n 5, a minimum of three sections per
animal) were analyzed by counting toluidine blue stained
normal myelin, thinly myelinated axons (denoting hypo-
myelination and potential remyelination), and preserved
demyelinated axons (with a total of five counts per sec-
tion taken).
Ventricle Ratio
For ventricle ratio analysis, brain sections were mounted
onto gelatin-coated microscope slides and allowed to dry
overnight. Slides were then dehydrated through increas-
ing alcohol before being immersed in H&E (1 minute).
Slides were then washed and excess staining was re-
moved before dehydrating in alcohol and finally in xylene
before using distyrene, platicizer, xylene (D.P.X.) moun-
tant mounting medium to mount glass coverslips. Slides
were allowed to dry overnight before being analyzed.
Ventricle surface areas and whole brain surface areas
were measured with stereology microscope (Olympus
with CAST-Grid analysis software). By dividing the ven-
tricle sizes by the whole brain sizes, ventricle ratios were
calculated.
NeuN Counts
For NeuN analysis, brain sections were washed in TBS
and subsequently blocked in TBS/0.2% Triton X-100/5%
normal donkey serum for 2 hours before overnight incu-
bation at 4°C with biotinylated NeuN (Millipore, Watford,
UK). Subsequently sections were washed in TBS, and
thereafter incubated with ABC kit (Vector, Peterborough,
UK 1:200) at room temperature for 2 hours. After two
washes with TBS and one with Tris-buffered non-saline,
the sections were briefly incubated with Sigma Fast 3,3-
diaminobenzidine (DAB, Sigma, Dorset, UK) and the re-
action stopped with Tris-buffered non-saline. After three
washes in Tris-buffered non-saline the sections were
mounted. Following mounting sections were dehydrated
through alcohols into xylene before using distyrene, pla-
ticizer, xylene (D.P.X.) mountant to mount glass cover-
slips. Following overnight drying the slides were used to
analyze neuronal nuclei in the parietal cortex of both
lesioned and transplanted groups.
Data Analysis
Images were captured using Lucia or Leica software
(Nikon, UK) via a digital camera. SigmaScan Pro (SPSS,
Chicago, IL) was used for subsequent quantitative mea-
surements. Immunopositive cell density measurements
were made on threshold overlays of brain segments sur-
rounding the corpus callosum and including ventricles
and periventricular areas (in which all pixels overlying
immunopositive cells had a greyscale value of 68, and all
other pixels had a value of 0), such that average intensity
could be converted to density measurements by dividing
the output by 68. This analysis used an automated
thresholding procedure.63,64 GFAP and OX-42 densito-
metric measurements were made on the resulting com-
bined threshold overlays as a function of distance from
the dorsal surface and through the corpus callosum re-
spectively. This method of quantification measures the
density of immunopositive objects independent of their
individual intensities. For NG2, Olig-2, and S100 analy-
ses, this technique was modified such that within the area
of interest, for each antibody stain, irrespective of the
density reading it was possible to define how much of the
area measured contained a positive signal, with raw im-
ages being thresholded before analysis to normalize the
results. A percentage of the brain segment containing a
positive antibody signal could be generated by dividing
the number of positive readings by the total number of
potential readings, multiplied by 100. A minimum of four
sections per animal were analyzed and for each section
readings were taken at similar positions through the cor-
tex, corpus callosum, ventricle, and periventricular areas
from which a mean percentage area of the dorsal funic-
ulus containing a positive signal could be calculated,
allowing comparisons between LPS-lesioned and vehicle
control animals. Averaged GFAP and OX-42 cell density
measurements were plotted as line graphs of density of
signal against depth and percentage changes as bar
graphs (Sigma Plot, SPSS, Chicago, IL). Statistical anal-
ysis was performed using one way analysis of variance
(with the Holm-Sidak posthoc analysis) or t-test and sig-
nificance was only assumed if P  0.01 (SigmaStat 3.0).
All error bars represent SE.
Results
Unilateral LPS Injection Leads to Bilateral
Ventricle Dilatation
The subchronic consequences of LPS-induced injury in
neonatal rats were first characterized. Animals were ex-
amined 8 weeks after unilateral injections of vehicle sa-
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line (n  6) or LPS (n  8) (10 mg/kg). Stereological
analysis of H&E-stained brain section undertaken to com-
pare whole brain and ventricle sizes revealed no signifi-
cant differences in coronal brain size between lesion or
control groups at 8 weeks (Figure 1C). However, an
average increase in ventricle size of 187% was observed
(Figure 1F). Unilateral injection of LPS resulted in signif-
icant bilateral ventricle enlargement while saline did not
alter ventricle size (Figure 1, A–B, D–E). This enlargement
of ventricles led to a significant increase in ventricle ratio
(ventricle size/whole brain) with an average of threefold
increase in ventricle ratio in the LPS-injected group com-
pared with vehicle control (Figure 1F, P  0.01).
Pathological Characterization
Having established ventriculomegaly we next undertook
detailed histology at 8 weeks. Astrogliosis was measured
using GFAP immunoreactivity. A significant increase in
GFAP immunoreactivity was observed at 8 weeks follow-
ing LPS lesioning (Figure 2A–B, E, P  0.01). Addition-
ally, the LPS-injected group showed a higher percentage
area with S100-positive signal, as compared with vehicle
control group, further confirming increased reactive as-
trocytosis (data not shown). Inflammation, as measured
by the activated microglial marker OX-42, was signifi-
cantly elevated in LPS-lesioned animals compared with
vehicle control (Figure 2, C, D, F, P  0.01). Semiquan-
titative PCR analysis also revealed that regions of the
brain surrounding the epicenter of the LPS injection sites
had higher levels of mRNA for IL-1 and TNF compared
with corresponding areas in the vehicle control groups
(Figure 2G). NG2 and Olig2 immunoreactivity, studied to
quantify oligodendrocyte lineage cell loss, was signifi-
cantly lower in LPS-lesioned animals than in vehicle con-
trol at 8 weeks in areas around the periventricular white
matter (Figure 3, A–C, D–F respectively, P  0.01). Semi-
thin analysis of toluidine blue-stained sections revealed
significantly thinner hypomyelinated axons in LPS-le-
sioned animals, as compared with the vehicle control
(see Supplemental Figure 2, P  0.05, at http://ajp.amj-
pathol.org) and a decrease in the total number of surviv-
ing axons in LPS-lesioned animals (93.9  0.7% and
96.4  0.5% respectively, P  0.05).
To determine neuronal pathology we undertook stereo-
logical NeuN analysis and quantitative neurofilament im-
munohistochemistry. Significant cortical neuronal loss
(1.40  106), as compared with vehicle control animals
(1.88  106) was evident at 8 weeks following LPS le-
sioning (Figure 4, A–C, P 0.01). This was accompanied
by a significant reduction in cortical neurofilament
(NF200) staining, which was not observed in the vehicle
control animals (Figure 4, D–F, P  0.01).
Together these findings suggest that 8 weeks after
unilateral LPS lesion, key chronic histological aspects of
PVL persist including bilateral ventriculomegaly, astro-
gliosis, inflammation, oligodendrocyte loss, and neuronal
loss.
Oligodendrocyte Precursor Cell Isolation and
Characterization
To test whether OPC transplantation may influence the
longer-term, subchronic effects of LPS-mediated injury,
we next isolated enriched OPCs. Before transplantation
paired aliquots of freshly isolated minimally manipulated
GFP-OPCs derived from standard neonatal mixed glial
preparations62 were characterized. Following plating for
24 hours, the majority of cells expressed the antigens
Figure 1. Unilateral LPS injury results in bilateral ventricle dilation. Tissue sections from LPS-lesioned (n  8) and vehicle control (n  8) animals were
stained using H&E and stereology software was used to measure whole brain sizes and ventricle ratios. H & E analysis revealed that compared with vehicle
control (A–B), unilateral LPS lesioning resulted in bilateral enlargement of the ventricles (D–E). The average coronal brain size did not differ between
groups (C). However, a significant increase in ventricle ratio of almost threefold was observed in LPS-lesioned animals at 8 weeks post-lesioning (F, * P 
0.01). Scale bar  500 m.
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NG2 (96.0  2.63%) and Olig2 and A2B5 (93.2 
5.37%), consistent with an OPC phenotype (see Supple-
mental Figure 3, A–C, F, at http://ajp.amjpathol.org).
GFAP cells made up 1% of the population in vitro
(0.65  0.51%). The remainder of cells were identified as
differentiating oligodendrocyte lineage cells, expressing
O4 (5.70  2.90%, see Supplemental Figure 3D at http://
ajp.amjpathol.org). No neuronal differentiation was ob-
served. All subsequent experiments used the highly en-
riched minimally manipulated OPC population without
further in vitro propagation or ‘priming’ treatment steps
before transplantation.
Graft-Derived GFP Cells Survive, Integrate and
Retain a Glial Fate Following Transplantation
into LPS-Lesioned Neonatal Rat Brain
One week following LPS lesioning at P5, animals received
unilateral delivery of either vehicle control (n  8) or
GFP-cell transplantation (n  8) adjacent to the LPS
injection. Animals were sacrificed 7 weeks after trans-
plantation (8 weeks post-lesioning). A substantial number
of engrafted GFP cells were observed in transplanted
animals (Figure 5A). GFP cells were primarily identified
within the periventricular white matter and were also ob-
served to be migrating along the white matter tract of the
cingulum around the periphery of enlarged ventricles
confirming engraftment and integration into the host ne-
onate. The overwhelming majority of GFP (green) cells
co-expressed NG2 (Figure 5, B and F) and Olig2 (Figure
5, C and F). Co-staining was confirmed by confocal mi-
croscopy (Figure 5, B–C) GFP cells were also identified
co-expressing further markers of the oligodendrocyte
lineage (RIP and O4, Supp. Figure 4 at http://ajp.
amjpathol.org). GFP cells were also identified by confo-
cal analysis in close proximity to astrocytes and indeed a
small number co-localized with the astrocytic marker
GFAP (Figure 5, D and F, Supplemental Figure 3 at
http://ajp.amjpathol.org). Importantly, GFP cells were
negative for the neuronal markers doublecortin, NF200,
SMI 32, and NeuN (Figure 5, E and F, Supplemental
Figure 4 at http://ajp.amjpathol.org).
OPC-Transplantation Reduces Endogenous
Neuronal and Oligodendrocyte Cell Loss
Following LPS Lesion
Transplantation with GFP-OPCs did not reduce the ven-
tricle ratio following LPS lesion (see Supplemental Figure
5, A–C at http://ajp.amjpathol.org). Analysis of GFP cell-
transplanted animals and the saline-treated control group
revealed elevated astrogliosis 8 weeks after LPS lesion-
ing (data not shown). We examined whether OPC trans-
plantation prevented the loss of immature oligodendro-
cytes following LPS lesioning. Following transplantation
there was a significant increase in NG2-positive immuno-
reactivity, as compared with the control-treated animals
in regions adjacent and but not containing GFP-OPC
cells (Figure 6, A–D, P 0.01). Having confirmed grafted
GFP cells do not differentiate into neurons we next
investigated the neuroprotective potential of transplanted
GFP-OPCs by stereology and image-based threshold
analysis. Stereology counts of parietal cortex of LPS-
lesioned animals with and without GFP-OPC transplants
revealed that GFP-OPC treated animals had significantly
reduced loss of neurons compared with LPS lesion alone
animals in regions adjacent to the cellular transplant (Fig-
ure 7, A–D, P  0.01) and an increase in NF200 positive
signal compared with LPS alone was also observed (Fig-
ure 7, E–H, P  0.01). Together, these findings are con-
sistent with a neuroprotective effect of transplanted OPCs
independent of directed neuronal differentiation.
Discussion
We report longer term, subchronic characterization of a
neonatal LPS-induced rat model of PVL and show that
bilateral ventriculomegaly, inflammation, reactive astro-
gliosis, injury to immature oligodendrocytes, and neuro-
Figure 2. LPS injury results in astrogliosis and inflammation. Astrogliosis was
observed using GFAP immunoreactivity. LPS-lesioned animals had signifi-
cantly more immunoreactivity using imaging based-threshold analysis than
vehicle control animals (A–B, E, P 0.01). Inflammation, as measured by the
activated microglial marker OX-42 had a significantly higher immunoreactive
signal in LPS-lesioned animals, as compared with vehicle control 8 weeks
following injury at all depths from the corpus callosum surface (C–D, F, P 
0.01). Semiquantitative PCR analysis of brain regions surrounding the epi-
center of lesioning revealed significant increase of inflammatory cytokines
Il-1 and TNF- in the LPS lesioned animals compared with the vehicle
control (G). Scale bar  200 m.
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nal loss persists 8 weeks after lesioning. We demonstrate
unilateral transplantation of OPCs results in neuronal pro-
tection, an effect not due to cell replacement. These
findings demonstrate a neuroprotective effect of OPC
transplantation.
Periventricular leukomalacia is a major contributor to
cerebral palsy with approximately 50% of cerebral palsy
cases associated with PVL.2 Although PVL is a chronic
disorder, current animal models of white matter damage
generally model short-term injury typically focused on
Figure 3. LPS injury results in loss of oligodendrocyte precursors. Tissue sections were labeled for NG2 and Olig2 as markers of oligodendrocyte precursor cells
8 weeks following lesioning, and threshold analysis was performed. Analysis revealed that there was a significant loss in NG2 positive immunolabeling (A–C) and
Olig2-positive immunolabeling (D–F) in the LPS-lesioned animals, as compared with vehicle control. Scale bar  200 m, *P  0.01.
Figure 4. LPS injury results in cortical neuronal cell loss and reduced neurofilament. Eight weeks following injection with vehicle or LPS, brain sections were
labeled with NeuN before stereology-based analysis. LPS lesioning resulted in a significant reduction in cortical neuronal cells, as compared with vehicle control
at 8 weeks (A–C). This neuronal cell loss was accompanied by a reduction in immunoreactivity of NF200 following threshold analysis in the LPS-lesioned animals,
as compared with the vehicle control animals (D–F). Scale bar  200 m, *P  0.01.
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early time points in the course of disease progression
from 3 days to 3 weeks post-lesion.15,22,23,36,38,44,65 PVL
leads to chronic disease with long-term clinical implica-
tions and thus it is important to evaluate later time points.
In the current study we have extended the temporal
analysis of the consequence of LPS mediated injury to 8
weeks. We demonstrated that intracerebral injections of
LPS increased the ventricle size independent of any al-
teration in whole brain size at 8 weeks, as confirmed by
significant increases in bilateral ventricle ratios. These
findings are in agreement with those of previous studies
examining earlier time points in this model,20,23,40,44
where ventriculomegaly was observed and ratios were
up to 10-fold greater than control.44,66 This ventricle di-
lation may be the result of impaired myelination and white
matter rarefaction, which alters the tensile strength of the
Figure 5. GFP-OPCs survive transplantation for at least 8 weeks and commit to glial progeny. GFP cells were clearly visible in both gray and white matter at 8
weeks post-transplantation in lesioned animals (arrows, A n  8, where D: dorsal surface, V: ventral and CC: Corpus callosum). Using confocal imaging
GFP-positive () cells (green) were identified to express phenotypic markers for NG2-positive cells (arrowhead, red, B), Olig2-positive cells (arrowhead, red,
C) and GFAP positive astrocytes (arrowhead, red, D). No NeuN co-labeled cells were observed at 8 weeks (E). Semiquantitative analysis revealed the majority
of GFP-positive cells co-labeled with Olig2 and NG2, while none were NeuN co-labeled (F). In all images, Hoechst-positive nuclei were labeled in blue. (:1%,
:25%, :25 to 50%, :50 to 75%, :75% of GFP cells). Scale bar  200 m (A), 100 m (B, C, E) and 50 m (D).
Figure 6. GFP-OPC transplantation increases density of NG2-positive OPCs following LPS-lesion. Following LPS lesioning and transplantation, sacrificed animals
were analyzed for NG2 oligodendrocyte precursor cell loss at 8 weeks. Threshold analysis revealed a significant increase in NG2-positive immunolabeling, at every
depth from corpus callosum surface measured, (A–D, D, *P  0.01) in the LPS-lesioned animals (B, n  10) that received the GFP cell transplant, as compared
with saline treated control (C, n  10) animals. Scale bar  200 m.
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ventricular wall. LPS-induced inflammation also alters
fluid transport.11,12
The acute LPS-induced model of neonatal damage
leads to significant decreases in immature oligodendro-
cytes23 loss of neurons and axons42 and induction of
pro-inflammatory cytokines, TNF, IL-1, and IL-6.20 We
observed in the subchronic model, a persistent decrease
in NG2 and Olig2 signal, markers of immature oligoden-
drocyte cells indicating death or delayed development of
these cells that continues for at least 8 weeks after LPS
injury. This decrease is similar to that observed by others
using the LPS injury as an acute model. We also ob-
served that LPS-lesioned brains had a decrease in myelin
surrounding axons by semithin analysis. Similarly, we
observed a sustained level of astrogliosis for up to 8
weeks following LPS lesioning. This was accompanied by
significant inflammation in the LPS-injected but not con-
trol brains as shown by increased activated microglial
signal and elevated TNF and IL-1, which have previ-
ously been reported in the lesioned neonates at the acute
time points.20,23,44,45,66 Previous studies have identified
that the inflammatory environment caused by LPS leads
to white matter damage,40 but also neuronal and axonal
damage that correlates to the impaired physical devel-
opment and neurobehavior.42,66 We also report persis-
tent neuronal loss that extends to 8 weeks following LPS
injury. Together our pathological findings reveal that as-
trogliosis, inflammation, oligodendrocyte, and neuronal
loss persist at 8 weeks and thus allow more accurate
evaluation of putative neuroprotective therapies such as
cell transplantation. Longer term analysis into aged
adults would be of interest to determine whether neuronal
loss is progressive.
Previous studies using the acute LPS lesion have ob-
served beneficial effects with antioxidants and anti-in-
flammatory agents, such as -phenyl-n-tert-butyl-nitrone,
minocycline, and N-acetyl cysteine.1,40,66–68 However, to
the best of our knowledge, no cellular therapy to replace
or protect oligodendrocytes and neurons lost following
LPS-mediated injury has been described. In the current
study we examined whether OPC transplantation had any
therapeutic benefit. Previously the effects of both endog-
enous and exogenous OPCs following demyelination and
CNS lesioning have been observed.49–53 Cell therapy
has typically been used to replace lost and damaged
cells through targeted cellular differentiation. However,
accumulating evidence now reveals that exogenously
transplanted cells or endogenous cells stimulated in situ
are capable of a ‘bystander’ effect implicating progenitor
cell-mediated neuroprotection through mechanisms in-
dependent of targeted cell differentiation.54 OPCs se-
crete soluble factors that support neuronal survival.56–58
Transplanted highly enriched GFP predominantly
OPCs freshly isolated from mixed glial preparations sur-
vived and integrated into the LPS injured rat brain surviv-
ing for at least 8 weeks consistent with previous stud-
ies.51 Following transplantation many of the GFP-OPCs
retained an immature glial phenotype with no evidence of
co-localization with the neuronal markers doublecortin,
NeuN and NF200 or more mature oligodendrocytes. In
vitro inflammatory cytokines TNF and interferon- have
previously been shown to limit maturation of OPC cul-
tures,69 and thus may inhibit mature differentiation in vivo.
Furthermore, we have previously reported limited matu-
ration of OPCs on transplantation into the intact neonatal
and adult rat brain.62 Following transplantation we ob-
served no change in GFAP immunoreactivity compared
with saline treated controls although a significantly higher
density of NG2 immunoreactivity was observed 8 weeks
post-lesioning. Previous studies have reported endog-
enous and exogenous OPC recruitment to regions of
damage following delivery of a therapy and promote
repair.52,53,70,71
Figure 7. GFP-OPC transplantation reduces neuronal loss. Following LPS lesioning and transplantation, sacrificed animals were analyzed for neuronal cell loss
using NeuN and NF200. GFP-OPC transplantation was observed to significantly reduce cortical neuronal loss, as compared with saline-treated lesioned animals
(A–D). Using stereology software, NeuN-positive cell counts were significantly higher in GFP-OPC transplanted groups than LPS alone (A–D, *P  0.01).
Neuroprotection of neuronal filaments from transplanted GFP-OPCs was also observed with an increase in neurofilament (NF200) immunoreactivity, as compared
with LPS lesion alone (E–H). Scale bar  200 m.
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Importantly, in the current study we observed signifi-
cant protection from neuronal (NeuN) and axonal
(NF200) loss following transplantation of GFP-OPCs into
the LPS-lesioned rat brain. The failure to identify any
GFP-OPCs co-labeled with NeuN, doublecortin or NF200
suggests that the effect on protecting/reducing the neu-
ronal deficits following transplantation are not due to cell
replacement cells but due to indirect tissue protection
mediated most likely by amelioration of the local environ-
ments. This phenomenon is known as a bystander effect.
These attributes have previously been observed follow-
ing OPC transplantation into both demyelinating lesions
where OPCs and myelin are specifically lost49 and in
CNS injuries where neuronal populations are targeted.50
Although transplantation did not reduce the ventricle
ratio of LPS-lesioned animals, we conclude that OPC
transplantation can protect the immature oligodendro-
cyte and neuronal deficits in a long term model of neo-
natal white matter damage. Furthermore, to enhance the
beneficial effects, combination of therapies using antioxi-
dants and/or anti-inflammatory agents could help reduce
the ventriculomegaly while the cellular therapy reduces
OPC loss and neuronal damage.
To conclude, we have demonstrated that the LPS-
induced rodent model of PVL can be extended to
‘chronic’ stages with continued oligodendrocyte and
neuronal loss. Moreover, we have shown that OPC-
transplantations have a protective effect on neurons
and oligodendrocytes. These findings open the way to
study therapeutic strategies for PVL-like white and gray
matter injury on a long-term rodent model and have
implications for the development of cell-based treat-
ment strategies for PVL.
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